Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme “unlocking the $1 Trillion Wealth ...
ahajournals.org

Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement ...

Cardiovascular disease and cancer are the leading causes of death in the United States, and hormone-dependent cancers (breast and prostate cancer) are the most common noncutaneous malignancies in ...

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...

Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada

Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.

Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment

Apotex Inc's ("Apotex") Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to ...

Everything about testosterone you didn’t know (but probably should)

This article was reviewed by Felix Gussone, MD. What Is Testosterone? As the primary male hormone, or androgen, testosterone ...

Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX ® ...